Osteosarcoma

Oncology·MeSH: Osteosarcoma

Prevalence

5.0 / 100K

16 drugs in development·12 companies·14 clinical trials

Drug Pipeline by Phase

Approved(3)

Drug	Company
canine osteosarcoma vaccine	ARATANA THERAPEUTICS, INC. (PETX)
leucovorin calcium preservative free	Mylan II B.V. (MYL)
leucovorin calcium preservative free	Seagen Inc. (SGEN)

Phase 3(3)

Drug	Company
azenosertib	Zentalis Pharmaceuticals, Inc. (ZNTL)
azenosertib (ZN-c3)	Zentalis Pharmaceuticals, Inc. (ZNTL)
Cabozantinib S-malate	Valneva SE (VALN)

Phase 2(2)

Drug	Company
Cabozantinib S-malate	Assertio Holdings, Inc. (ASRT)
ost-her2	OS Therapies Inc (OSTX)

Phase 1(3)

Drug	Company
adxs-her2	OLD AYALA, INC (AYLA)
ADXS-HER2 (ADXS31-164)	Ayala Pharmaceuticals, Inc. (ADXS)
FH FOLR1 ST CAR T-cells	Filana Therapeutics Inc. (FLNA)

Preclinical(4)

Unknown(1)

Drug	Company
AT-014	Ayala Pharmaceuticals, Inc. (ADXS)

BioSniper tracks 16 drugs in development for Osteosarcoma across 12 companies.

There are 14 clinical trials targeting Osteosarcoma tracked by BioSniper.

The estimated prevalence of Osteosarcoma is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.